JP2010500365A
(ja)
|
2006-08-07 |
2010-01-07 |
インサイト・コーポレイション |
キナーゼ阻害剤としてのトリアゾロトリアジン
|
WO2008027812A2
(en)
*
|
2006-08-28 |
2008-03-06 |
Forest Laboratories Holdings Limited |
Imidazopyridine and imidazopyrimidine derivatives
|
AU2007323725B2
(en)
|
2006-11-22 |
2014-02-20 |
Incyte Holdings Corporation |
Imidazotriazines and imidazopyrimidines as kinase inhibitors
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
WO2009032754A2
(en)
*
|
2007-08-31 |
2009-03-12 |
Kalypsys, Inc. |
Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
|
NZ602791A
(en)
|
2008-05-21 |
2014-04-30 |
Incyte Corp |
Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
|
RU2011123647A
(ru)
|
2008-11-10 |
2012-12-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Соединения, полезные в качестве ингибиторов atr киназы
|
WO2010067131A1
(en)
|
2008-12-11 |
2010-06-17 |
Respivert Limited |
P38 map kinase inhibitors
|
SG10201607592PA
(en)
|
2008-12-19 |
2016-11-29 |
Vertex Pharma |
Pyrazine derivatives useful as inhibitors of atr kinase
|
WO2010079241A1
(es)
*
|
2009-01-12 |
2010-07-15 |
Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion |
Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
|
ES2475091T3
(es)
|
2009-04-16 |
2014-07-10 |
Centro Nacional De Investigaciones Oncol�Gicas (Cnio) |
Imidazopirazinas como inhibidores de proteína cinasas
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
EA025304B1
(ru)
|
2010-02-03 |
2016-12-30 |
Инсайт Холдингс Корпорейшн |
ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
|
WO2011143423A2
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2011143399A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2569289A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Pyrazines useful as inhibitors of atr kinase
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
MX2012013082A
(es)
|
2010-05-12 |
2013-05-09 |
Vertex Pharma |
Derivados de 2-aminopiridina utiles como iinhibidores de cinasa atr.
|
CA2798763A1
(en)
|
2010-05-12 |
2011-11-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
CA2803802A1
(en)
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
EP2444084A1
(en)
|
2010-10-21 |
2012-04-25 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Use of PI3K inibitors for the treatment of obesity
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
KR101326557B1
(ko)
*
|
2011-03-31 |
2013-11-08 |
주식회사종근당 |
카나비노이드 수용체〔cbi〕길항제로서의 벤즈아미드 유도체
|
KR20140027974A
(ko)
|
2011-04-05 |
2014-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
Tra 키나제의 억제제로서 유용한 아미노피라진 화합물
|
JP2014517079A
(ja)
|
2011-06-22 |
2014-07-17 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
JP2014520161A
(ja)
|
2011-06-22 |
2014-08-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
EP2940017B1
(en)
|
2011-09-30 |
2019-08-28 |
Vertex Pharmaceuticals Incorporated |
Process for making compounds useful as inhibitors of ATR kinase
|
EP2751099B1
(en)
|
2011-09-30 |
2017-06-14 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
EP2751088B1
(en)
|
2011-09-30 |
2016-04-13 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2013049859A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
EP2776422A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
EP2776420A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
WO2013071094A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
JP2015502925A
(ja)
|
2011-11-09 |
2015-01-29 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用なピラジン化合物
|
CN104066735B
(zh)
|
2012-01-10 |
2016-08-31 |
拜耳知识产权有限责任公司 |
作为akt激酶抑制剂的取代的咪唑并吡嗪
|
CN108478577A
(zh)
|
2012-04-05 |
2018-09-04 |
沃泰克斯药物股份有限公司 |
可用作atr激酶抑制剂的化合物及其组合疗法
|
WO2014055756A1
(en)
|
2012-10-04 |
2014-04-10 |
Vertex Pharmaceuticals Incorporated |
Method for measuring atr inhibition mediated increases in dna damage
|
EP2909202A1
(en)
|
2012-10-16 |
2015-08-26 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
ES2655030T3
(es)
|
2012-11-19 |
2018-02-16 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de enfermedades parasitarias
|
LT3418281T
(lt)
|
2012-12-07 |
2021-01-11 |
Vertex Pharmaceuticals Inc. |
Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
|
CN103012284A
(zh)
*
|
2012-12-26 |
2013-04-03 |
无锡捷化医药科技有限公司 |
一种2-氨基-5-溴嘧啶类化合物的制备方法
|
RU2644769C2
(ru)
|
2013-01-23 |
2018-02-14 |
Астразенека Аб |
Химические соединения
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
PT3077397T
(pt)
|
2013-12-06 |
2020-01-22 |
Vertex Pharma |
Composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor da atr quinase, a sua preparação, diferentes formas sólidas e derivados radiomarcados do mesmo
|
GB201321736D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic agents
|
RS60013B1
(sr)
|
2014-06-05 |
2020-04-30 |
Vertex Pharma |
Radioaktivno obeleženi derivati jedinjenja 2-amino-6-fluoro-n-[5-fluoropiridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida, korisnog kao inhibitora atr kinaze, dobijanje pomenutog jedinjenja i njegovi različiti čvrsti oblici
|
CA2950780C
(en)
|
2014-06-17 |
2023-05-16 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of chk1 and atr inhibitors
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
EP3365340B1
(en)
|
2015-10-19 |
2022-08-10 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
HRP20221035T1
(hr)
|
2015-11-19 |
2022-11-11 |
Incyte Corporation |
Heterociklički spojevi kao imunomodulatori
|
PE20230731A1
(es)
|
2015-12-22 |
2023-05-03 |
Incyte Corp |
Compuestos heterociclicos como inmunomoduladores
|
AR108396A1
(es)
|
2016-05-06 |
2018-08-15 |
Incyte Corp |
Compuestos heterocíclicos como inmunomoduladores
|
EP3464279B1
(en)
|
2016-05-26 |
2021-11-24 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
TWI771305B
(zh)
|
2016-06-20 |
2022-07-21 |
美商英塞特公司 |
作為免疫調節劑之雜環化合物
|
US11352328B2
(en)
|
2016-07-12 |
2022-06-07 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus
|
WO2018013789A1
(en)
|
2016-07-14 |
2018-01-18 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
JP7212612B2
(ja)
|
2016-07-28 |
2023-01-25 |
プロメガ コーポレイション |
セレンテラジン類縁体
|
CN106317043B
(zh)
*
|
2016-08-19 |
2018-11-02 |
成都理工大学 |
一种大麻素受体2激动剂
|
CN106317059B
(zh)
*
|
2016-08-19 |
2018-10-12 |
成都理工大学 |
一种大麻素受体2(cb2)激动剂
|
US20180057486A1
(en)
|
2016-08-29 |
2018-03-01 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
ES2874756T3
(es)
|
2016-12-22 |
2021-11-05 |
Incyte Corp |
Derivados de triazolo[1,5-A]piridina como inmunomoduladores
|
WO2018119266A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
PE20200005A1
(es)
|
2016-12-22 |
2020-01-06 |
Incyte Corp |
Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de internalizacion pd-l1
|
WO2018119221A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Pyridine derivatives as immunomodulators
|
FI3774791T3
(fi)
|
2018-03-30 |
2023-03-21 |
Incyte Corp |
Heterosyklisiä yhdisteitä immunomodulaattoreina
|
BR112020022936A2
(pt)
|
2018-05-11 |
2021-02-02 |
Incyte Corporation |
derivados de tetra-hidro-imidazo[4,5-c]piridina como imunomoduladores de pd-l1
|
GB201811695D0
(en)
|
2018-07-17 |
2018-08-29 |
Salvensis |
Compounds for use in the treatment of fascioliasis
|
WO2021030162A1
(en)
|
2019-08-09 |
2021-02-18 |
Incyte Corporation |
Salts of a pd-1/pd-l1 inhibitor
|
JP7559059B2
(ja)
|
2019-09-30 |
2024-10-01 |
インサイト・コーポレイション |
免疫調節剤としてのピリド[3,2-d]ピリミジン化合物
|
MX2022005651A
(es)
|
2019-11-11 |
2022-07-27 |
Incyte Corp |
Sales y formas cristalinas de un inhibidor de la proteina de muerte celular programada 1 (pd-1)/ligando de muerte celular programada 1 (pd-l1).
|
TW202233615A
(zh)
|
2020-11-06 |
2022-09-01 |
美商英塞特公司 |
Pd—1/pd—l1抑制劑之結晶形式
|
KR20230117573A
(ko)
|
2020-11-06 |
2023-08-08 |
인사이트 코포레이션 |
Pd-1 및 pd-l1 억제제, 및 이의 염 및 결정형의 제조 방법
|
US11780836B2
(en)
|
2020-11-06 |
2023-10-10 |
Incyte Corporation |
Process of preparing a PD-1/PD-L1 inhibitor
|
WO2024023266A1
(en)
*
|
2022-07-28 |
2024-02-01 |
Ac Immune Sa |
Novel compounds
|